Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01954147

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Diabetes Care Center of Nanjing Military Command (from the registry)
Registry
  • NCT NCT01954147
Other papers using this trial's data
  • [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus] Zhonghua nei ke za zhi, 2016-05-01 DOI, PubMed 27143183

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01954147. Non-randomized; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus
Intervention (Drug)
GLP-1
Intervention (Biological)
SC
Intervention (Other)
Standard Medical Treatment
Lead sponsor
Diabetes Care Center of Nanjing Military Command (class: other)

Record details

Record id
cardio:ct-nct01954147
Content hash
e9e24d6787d1cdb3b9e98501c51fe82489a2ffa2785fa33d7a55c489f7f8fec9